Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Moik, F; Riedl, JM; Winder, T; Terbuch, A; Rossmann, CH; Szkandera, J; Bauernhofer, T; Kasparek, AK; Schaberl-Moser, R; Reicher, A; Prinz, F; Pichler, M; Stöger, H; Stotz, M; Gerger, A; Posch, F.
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Sci Rep. 2019; 9(1):5548
Doi: 10.1038/s41598-019-42069-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Moik Florian
- Posch Florian
- Co-authors Med Uni Graz
- Bauernhofer Thomas
- Gerger Armin
- Kasparek Anne-Katrin
- Pichler Martin
- Prinz Felix
- Reicher Andreas
- Riedl Jakob
- Schaberl-Moser Renate
- Stöger Herbert
- Stotz Michael
- Szkandera Joanna
- Terbuch Angelika
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Whether 2nd-line-chemotherapy (2LCTX) + best-supportive-care (BSC) benefits patients with advanced biliary tract cancer (aBTC) more than BSC alone is unclear. We therefore conducted a propensity-score-based comparative effectiveness analysis of overall survival (OS) outcomes in 80 patients with metastatic, recurrent, or inoperable aBTC, of whom 38 (48%) were treated with BSC + 2LCTX and 42 (52%) with BSC alone. After a median follow-up of 14.8 months and 49 deaths, the crude 6-, 12-, and 18-month Kaplan-Meier OS estimates were 77%, 53% and 23% in the BSC + 2LCTX group, and 29%, 21%, and 14% in patients in the BSC group (p = 0.0003; Hazard ratio (HR) = 0.36, 95%CI:0.20-0.64, p = 0.001). An inverse-probability-of-treatment-weighted (IPTW) analysis was conducted to rigorously account for the higher prevalence of favorable prognostic variables in the 2LCTX + BSC group. After IPTW-weighting, the favorable association between 2LCTX and OS prevailed (adjusted HR = 0.40, 95%CI: 0.17-0.95, p = 0.037). IPTW-weighted 6-, 12-, and 18-month OS estimates were 77%, 58% and 33% in the BSC + 2LCTX group, and 39%, 28% and 22% in the BSC group (p = 0.037). Moreover, the benefit of 2LCTX was consistent across several clinically-relevant subgroups. Within the limitations of an observational study, these findings support the concept that 2LCTX + BSC is associated with an OS benefit over BSC alone in aBTC.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Biliary Tract Neoplasms - drug therapy, mortality, pathology
- Cisplatin - administration & dosage
- Deoxycytidine - administration & dosage, analogs & derivatives
- Female - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Palliative Care - administration & dosage
- Propensity Score - administration & dosage
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage